Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD

Thyroid hormones control lipid metabolism by exhibiting specific effects on the liver and adipose tissue in a coordinated manner. Different diseases of the thyroid gland can result in hypothyroidism. Hypothyroidism is frequently associated with dyslipidemia. Hypothyroidism-associated dyslipidemia su...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2021-11, Vol.22 (23), p.12797
Main Authors: Mavromati, Maria, Jornayvaz, François R
Format: Article
Language:English
Subjects:
Accumulation
Adipose tissue
Animals
Body fat
Cholesterol
Dyslipidemia
Dyslipidemias - etiology
Dyslipidemias - pathology
Enzymes
Fatty acids
Fatty liver
Gene expression
High density lipoprotein
Hormones
Humans
Hyperthyroidism
Hypothyroidism
Hypothyroidism - complications
Insulin
Insulin Resistance
Lipid Metabolism
Lipids
Liver
Liver diseases
Low density lipoprotein
Metabolic disorders
Metabolism
Metabolites
Molecular modelling
NAFLD
Non-alcoholic Fatty Liver Disease - etiology
Non-alcoholic Fatty Liver Disease - pathology
Oxidation
Oxidative stress
Proteins
Review
Risk analysis
Risk Factors
Sterols
Thyroid gland
Thyroid hormones
Transcription factors
Triglycerides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thyroid hormones control lipid metabolism by exhibiting specific effects on the liver and adipose tissue in a coordinated manner. Different diseases of the thyroid gland can result in hypothyroidism. Hypothyroidism is frequently associated with dyslipidemia. Hypothyroidism-associated dyslipidemia subsequently results in intrahepatic accumulation of fat, leading to nonalcoholic fatty liver disease (NAFLD), which leads to the development of hepatic insulin resistance. The prevalence of NAFLD in the western world is increasing, and evidence of its association with hypothyroidism is accumulating. Since hypothyroidism has been identified as a modifiable risk factor of NAFLD and recent data provides evidence that selective thyroid hormone receptor β (THR-β) agonists are effective in the treatment of dyslipidemia and NAFLD, interest in potential therapeutic options for NAFLD targeting these receptors is growing. In this review, we summarize current knowledge regarding clinical and molecular data exploring the association of hypothyroidism, dyslipidemia and NAFLD.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms222312797